Data collection
Relevant data were retrospectively retrieved from medical records at
baseline visit (defined as the first consultation in our centre) and up
until the last follow-up visit. At baseline, we collected patient
characteristics (age, gender, previous medical history of relevant
conditions), treatment data (date of introduction and withdrawal of
bradykinin-releasing drugs, antihistamines, corticosteroids and/or
non-steroidal anti-inflammatory drugs (NSAIDs)), AE attack
characteristics (total number, triggering factors, prodromes,
localization, associated signs, duration, attack treatments) and
biological results (serum complement, eosinophils, immunoglobulin E
(IgE), tryptase, thyroid-stimulating hormone (TSH), anti-thyroglobulin
and anti-thyroperoxydase levels). During follow-up, we assessed ACEi
discontinuation and/or re-exposure, recurrence of AE attacks (and their
characteristics), occurrence of atopic manifestations and/or typical
lesions of urticaria and therapeutic data (treatment by
bradykinin-releasing drugs, antihistamines, corticosteroids and/or
NSAIDs).